[{"id":"ba1d77c6-9119-4611-81e5-4c119bce9349","acronym":"","url":"https://clinicaltrials.gov/study/NCT05212584","created_at":"2022-01-29T18:05:33.757Z","updated_at":"2024-07-02T16:36:07.736Z","phase":"Phase 1","brief_title":"CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma","source_id_and_acronym":"NCT05212584","lead_sponsor":"iCell Gene Therapeutics","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 CAR-T Cell"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-07-06"},{"id":"c2090d5e-7292-43af-893a-cbc09a14a0bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04934774","created_at":"2021-06-22T15:52:44.392Z","updated_at":"2024-07-02T16:36:28.816Z","phase":"Phase 1","brief_title":"Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances","source_id_and_acronym":"NCT04934774","lead_sponsor":"iCell Gene Therapeutics","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 CAR-T Cell"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2021-06-22"}]